Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Return on Sales (2023 - 2025)

Historic Return on Sales for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to 0.28%.

  • Axsome Therapeutics' Return on Sales rose 3400.0% to 0.28% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.41%, marking a year-over-year increase of 5100.0%. This contributed to the annual value of 0.74% for FY2024, which is 1400.0% up from last year.
  • Per Axsome Therapeutics' latest filing, its Return on Sales stood at 0.28% for Q3 2025, which was up 3400.0% from 0.32% recorded in Q2 2025.
  • Axsome Therapeutics' Return on Sales' 5-year high stood at 0.12% during Q1 2023, with a 5-year trough of 4.7% in Q2 2022.
  • Moreover, its 4-year median value for Return on Sales was 0.91% (2024), whereas its average is 1.29%.
  • As far as peak fluctuations go, Axsome Therapeutics' Return on Sales skyrocketed by 32600bps in 2023, and later crashed by -7900bps in 2024.
  • Over the past 4 years, Axsome Therapeutics' Return on Sales (Quarter) stood at 2.51% in 2022, then soared by 45bps to 1.38% in 2023, then soared by 54bps to 0.63% in 2024, then surged by 56bps to 0.28% in 2025.
  • Its Return on Sales was 0.28% in Q3 2025, compared to 0.32% in Q2 2025 and 0.49% in Q1 2025.